The success of the anti-VEGF plus PD-L1 dual blockade regimen in the first-line treatment of advanced hepatocellular carcinoma (IMbrave150 study) (30) marks an important change in the standard of care for advanced HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.